Cargando…
Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer()
BACKGROUND: IGFBP-3 is a multifunctional protein that inhibits growth and induces apoptosis of cancer cells. Hypermethylation of the promoter represses expression of the IGFBP-3 gene. We undertook this study to assess the impact of IGFBP-3 methylation on survival of early stage gastric cancer patien...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562974/ https://www.ncbi.nlm.nih.gov/pubmed/26310375 http://dx.doi.org/10.1016/j.tranon.2015.06.001 |
_version_ | 1782389217900363776 |
---|---|
author | Kim, Seung Tae Jang, Hye-Lim Lee, Jeeyun Park, Se Hoon Park, Young Suk Lim, Ho Yeong Choi, Min Gew Bae, Jae Moon Sohn, Tae Sung Noh, Jae Hyung Kim, Sung Kim, Kyoung-Mee Kang, Won Ki Park, Joon Oh |
author_facet | Kim, Seung Tae Jang, Hye-Lim Lee, Jeeyun Park, Se Hoon Park, Young Suk Lim, Ho Yeong Choi, Min Gew Bae, Jae Moon Sohn, Tae Sung Noh, Jae Hyung Kim, Sung Kim, Kyoung-Mee Kang, Won Ki Park, Joon Oh |
author_sort | Kim, Seung Tae |
collection | PubMed |
description | BACKGROUND: IGFBP-3 is a multifunctional protein that inhibits growth and induces apoptosis of cancer cells. Hypermethylation of the promoter represses expression of the IGFBP-3 gene. We undertook this study to assess the impact of IGFBP-3 methylation on survival of early stage gastric cancer patients. METHODS: Of the 482 tissue samples from gastric cancer patients who underwent curative surgery, IGFBP-3 methylation was tested in 138 patients with stage IB/II gastric cancer. We also analyzed IGFBP-3 methylation in 26 gastric cancer cell lines. IGFBP-3 methylation was evaluated by methylation-specific polymerase chain reaction (MethyLight). Statistical analyses, all two-sided, were performed to investigate the prognostic effects of methylation status of the IGFBP-3 promoter on various clinical parameters. RESULTS: Hypermethylation of IGFBP-3 was observed in 26 (19%) of the 138 stage IB/II gastric cancer patients. Clinicopathological factors such as age, Lauren classification, sex, tumor infiltration, lymph node metastasis, and histologic grade did not show a statistically significant association with the methylation status of the IGFBP-3 promoter. Patients with a hypermethylated IGFBP-3 promoter had similar 8-year disease-free survival compared with those without a hypermethylated IGFBP-3 promoter (73% vs 75%, P = .78). In subgroup analyses, females, but not males, seemed to have poorer prognosis for DFS and OS in the subset of patients with IGFBP-3 methylation as compared with those without IGFBP-3 methylation (8-year DFS: 55.6% vs 71.6%, P = .3694 and 8-year overall survival: 55.6% vs 68.4%, P = .491, respectively) even with no statistical significance. CONCLUSIONS: The status of IGFBP-3 methylation as measured by methylation-specific polymerase chain reaction proposed the modest role for predicting survival in specific subgroups of patients with early-stage gastric cancer who undergo curative surgery. However, this needs further investigation. |
format | Online Article Text |
id | pubmed-4562974 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Neoplasia Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-45629742015-09-29 Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer() Kim, Seung Tae Jang, Hye-Lim Lee, Jeeyun Park, Se Hoon Park, Young Suk Lim, Ho Yeong Choi, Min Gew Bae, Jae Moon Sohn, Tae Sung Noh, Jae Hyung Kim, Sung Kim, Kyoung-Mee Kang, Won Ki Park, Joon Oh Transl Oncol Article BACKGROUND: IGFBP-3 is a multifunctional protein that inhibits growth and induces apoptosis of cancer cells. Hypermethylation of the promoter represses expression of the IGFBP-3 gene. We undertook this study to assess the impact of IGFBP-3 methylation on survival of early stage gastric cancer patients. METHODS: Of the 482 tissue samples from gastric cancer patients who underwent curative surgery, IGFBP-3 methylation was tested in 138 patients with stage IB/II gastric cancer. We also analyzed IGFBP-3 methylation in 26 gastric cancer cell lines. IGFBP-3 methylation was evaluated by methylation-specific polymerase chain reaction (MethyLight). Statistical analyses, all two-sided, were performed to investigate the prognostic effects of methylation status of the IGFBP-3 promoter on various clinical parameters. RESULTS: Hypermethylation of IGFBP-3 was observed in 26 (19%) of the 138 stage IB/II gastric cancer patients. Clinicopathological factors such as age, Lauren classification, sex, tumor infiltration, lymph node metastasis, and histologic grade did not show a statistically significant association with the methylation status of the IGFBP-3 promoter. Patients with a hypermethylated IGFBP-3 promoter had similar 8-year disease-free survival compared with those without a hypermethylated IGFBP-3 promoter (73% vs 75%, P = .78). In subgroup analyses, females, but not males, seemed to have poorer prognosis for DFS and OS in the subset of patients with IGFBP-3 methylation as compared with those without IGFBP-3 methylation (8-year DFS: 55.6% vs 71.6%, P = .3694 and 8-year overall survival: 55.6% vs 68.4%, P = .491, respectively) even with no statistical significance. CONCLUSIONS: The status of IGFBP-3 methylation as measured by methylation-specific polymerase chain reaction proposed the modest role for predicting survival in specific subgroups of patients with early-stage gastric cancer who undergo curative surgery. However, this needs further investigation. Neoplasia Press 2015-08-24 /pmc/articles/PMC4562974/ /pubmed/26310375 http://dx.doi.org/10.1016/j.tranon.2015.06.001 Text en © 2015 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Kim, Seung Tae Jang, Hye-Lim Lee, Jeeyun Park, Se Hoon Park, Young Suk Lim, Ho Yeong Choi, Min Gew Bae, Jae Moon Sohn, Tae Sung Noh, Jae Hyung Kim, Sung Kim, Kyoung-Mee Kang, Won Ki Park, Joon Oh Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer() |
title | Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer() |
title_full | Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer() |
title_fullStr | Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer() |
title_full_unstemmed | Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer() |
title_short | Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer() |
title_sort | clinical significance of igfbp-3 methylation in patients with early stage gastric cancer() |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562974/ https://www.ncbi.nlm.nih.gov/pubmed/26310375 http://dx.doi.org/10.1016/j.tranon.2015.06.001 |
work_keys_str_mv | AT kimseungtae clinicalsignificanceofigfbp3methylationinpatientswithearlystagegastriccancer AT janghyelim clinicalsignificanceofigfbp3methylationinpatientswithearlystagegastriccancer AT leejeeyun clinicalsignificanceofigfbp3methylationinpatientswithearlystagegastriccancer AT parksehoon clinicalsignificanceofigfbp3methylationinpatientswithearlystagegastriccancer AT parkyoungsuk clinicalsignificanceofigfbp3methylationinpatientswithearlystagegastriccancer AT limhoyeong clinicalsignificanceofigfbp3methylationinpatientswithearlystagegastriccancer AT choimingew clinicalsignificanceofigfbp3methylationinpatientswithearlystagegastriccancer AT baejaemoon clinicalsignificanceofigfbp3methylationinpatientswithearlystagegastriccancer AT sohntaesung clinicalsignificanceofigfbp3methylationinpatientswithearlystagegastriccancer AT nohjaehyung clinicalsignificanceofigfbp3methylationinpatientswithearlystagegastriccancer AT kimsung clinicalsignificanceofigfbp3methylationinpatientswithearlystagegastriccancer AT kimkyoungmee clinicalsignificanceofigfbp3methylationinpatientswithearlystagegastriccancer AT kangwonki clinicalsignificanceofigfbp3methylationinpatientswithearlystagegastriccancer AT parkjoonoh clinicalsignificanceofigfbp3methylationinpatientswithearlystagegastriccancer |